Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.63 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.63 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 3/20 | 0.50 |
| ▸ | CPA3 | P15088 | 3/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CPB1 | P15086 | 1/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.50 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7436297 | 1.00 | SLC1A3 (0.63) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| SCHEMBL2243422 | 1.00 | SLC1A3 (0.63) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| SCHEMBL3867023 | 1.00 | SLC1A3 (0.63) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL2919214 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL4755513 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL305323 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| (2R,3R)-2,3-Dibenzylsuccinic Acid SCHEMBL7289849 | 0.87 | SLC1A3 (0.73) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| SCHEMBL9554592 | 0.86 | SLC1A3 (0.58) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| SCHEMBL7269073 | 0.85 | SLC1A3 (0.66) | SLC1A3SLC1A2SLC1A1CYP1A2ALPI | |
| SCHEMBL29365045 | 0.84 | ANPEP (0.51) | SLC1A3SLC1A2SLC1A1PTGS1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0379288-B1 | Process and intermediates for isopropyl 3S-amino-2R-hydroxyalkanoates | PFIZER (US) | 1993-12-22 | — | — | EP | claimed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
| US-5321143-A | Reacting tartaric acid, ester or amide with thionyl chloride; cyclization, in situ oxidation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-06-14 | — | — | US | disclosed |
| US-5166400-A | Intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates | PFIZER INC. (US) | 1992-11-24 | — | — | US | disclosed |
| US-5112990-A | Oxidation of cyclic sulfites produced from dihydroxy compounds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-05-12 | — | — | US | disclosed |
| US-5036155-A | Process for isopropyl 3S-amino-2R-hydroxy-alkanoates | PFIZER INC. (US) | 1991-07-30 | — | — | US | disclosed |
| US-5023342-A | Intermediates for antibiotics and pheronomes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-06-11 | — | — | US | disclosed |
| EP-0417187-A1 | RUTHENIUM-CATALYZED PRODUCTION OF CYCLIC SULFATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4965372-A | Process and intermediates for isopropyl 3S-amino-2R-hydroxy-alkanoates | PFIZER INC. (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0379288-A1 | Process and intermediates for isopropyl 3S-amino-2R-hydroxyalkanoates | PFIZER INC. (US) | 1990-07-25 | — | — | EP | disclosed |
| WO-1989011478-A1 | RUTHENIUM-CATALYZED PRODUCTION OF CYCLIC SULFATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | SLC1A3 1239/4885SLC1A2 1001/4885SLC1A1 839/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | SLC1A3 1256/4885SLC1A2 984/4885SLC1A1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.